Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has received FDA clearance to commence a phase IIa clinical trial in the US according to the Investigational New Drug (IND) application that was submitted in February 2023. The trial will test its lead neurological cell therapy product AstroRx ® in repeated dosing of three-month intervals for the treatment of patients with ALS. The planned clinical trial follows a first in human phase I/IIa clinical trial previously conducted by the company in Israel, in which AstroRx® was injected into the spinal cord fluid using a standard lumbar puncture procedure. In this phase I/IIa clinical trial Kadimastem demonstrated a good safety profile and clinically meaningful decline in the disease progression during the first 3-months follow-up period. AstroRx® contains functional, healthy astrocytes (nervous system supporting cells) differentiated from human Embryonic Stem Cells (hESC) that aim to support the survival of diseased motor neurons through several mechanisms of action. The treatment’s goal is to nourish and support the malfunctioning motor neurons in the brain and spinal cord of patients suffering from Amyotrophic Lateral Sclerosis (ALS), to significantly slow the progression of the disease and improve the quality of life and life expectancy of the treated patients. Kadimastem CEO Asaf Shiloni said, “The FDA approval for this multi-site clinical trial is a major achievement for us and is a recognition of our professional, clinical and scientific abilities. I’d like to congratulate our dedicated team on this extremely important landmark, which is an enormous milestone that brings great hope for the future of the ALS patients as well as our supporters and investors.” Kadimastem Founder and Chief Scientific Officer Professor Michel Revel said, “The approval of submission of the IND to the FDA is a major achievement and moment of pride for me in the company that I have founded years ago, with an amazing team. It is very exciting, and we eagerly await to start this trial and wish to help ALS patients as soon as possible.” About AstroRx ® & ALS Kadimastem’s flagship product, AstroRx®, is a breakthrough technology that is comprised of a unique and large cell population of astrocytes derived from human pluripotent stem cells. The cells are intended to support the survival of motoneurons (neurons the control the motor-capability) in the central nervous system (CNS, brain and spinal cord). AstroRx® enables the transplantation of healthy astrocytes into the CNS of the ALS patient and an improvement in the protection of the motoneurons. In December 2020, Kadimastem announced the results Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. of the first of its kind, Phase I/IIa clinical trial, in which healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal fluid of 10 ALS patients. Data showed that AstroRx® has the potential to slow the progression of ALS, as indicated by a clinical score called ALSFRS-R. Kadimastem plans to test repeated doses every three months of AstroRx® to achieve a continuous delay of the disease. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1601 s.bazak@kadimastem.com GOTLIVE Media Group Lior Gottlieb +972 50-920-0194 lior@gotlive-ir.co.il Company Website https://www.kadimastem.com/

March 20, 2023 07:00 AM Eastern Daylight Time

AMERICAN DIVERSIFIED HOLDINGS CORP (OTC: ADHC) REACHES AGREEMENT FOR COMPREHENSIVE TRANSITION OF ALL BUSINESS OPERATIONS

American Diversified Holdings Corp.

McapMediaWire -- American Diversified Holdings Corporation (OTC: ADHC ) announced today that the Company has filed its quarterly financials ending in 1-31-23. The filing can be found at www.otcmarkets.com under the ticker symbol "ADHC". Additionally plans to divest of all operating business have been initiated in anticipation of a comprehensive transition of all company operations. Agreements have been reached for a new CEO, a New Advisory Board and a new operating business. Additionally, ADHC management has been advised by litigation counsel that a judicial order cancelling 325 mm shares of common stock is expected imminently. Parties a have agreed to refrain from publicizing any details of these agreements until formal execution has taken place. It is anticipated that all developments should be consummated in April, 2023. ADHC has filed suit in The Eight Judicial Circuit Court, Clark County, Nevada case, Number A-21-843-670, seeking the cancellation of 325,000,000 (325 MM) shares of common stock. On January 6, 2023, the court granted the motion for default and will be issuing the formal order soon. The signed court order granting default judgment is the final legal step before all litigation is resolved. Currently, ADHC capitalization structure is as follows: Shares Outstanding: 1.1 billion Shares Restricted: 600 million Shares in the Float: 504 million GLOBAL CBD PET INDUSTRY OVERVIEW: GLOBAL CBD PET MARKET: $198MM 2022; $248MM 2023; $2 BILLION 2030 ANNUAL GROWTH RATE: 31.8 % COMPOUNDED ANNUAL GROWTH RATE E-COMMERCE SEGMENT: 42% OF REVENUES INDICATION: JOINT PAIN, ANXIETY/STRESS, EPILEPSY, GENERAL HEALTH AND WELLNESS see https://www.grandviewresearch.com/industry-analysis/cannabidiol-pet-market About ADHC: American Diversified Holdings Corporation (OTC: ADHC) is a publicly traded holding company trading under the ticker symbol "ADHC". Investor Contact: Ernest Remo Chairman/CEO EMAIL: ernestremo@san.rr.com Tel: 858-259-4534 TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different from the performance or achievements expressed. You should not place undue reliance on these statements since they involve known and unknown risks, in some cases, beyond our control. Contact Details Ernest Remo +1 858-259-4534 ernestremo@san.rr.com Company Website https://rollschoiceadhesive.com/

March 20, 2023 06:30 AM Eastern Daylight Time

News Release

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

BioVaxys Technology Corp

BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET) technology platform. Passin says the acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting its core business in cancer and viral vaccine development. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 17, 2023 12:08 PM Eastern Daylight Time

Video

News Release

Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022. Saviuk tells Proactive this marks the 5th consecutive quarter of growth for the company, with adjusted gross profit increasing by 178% to $4.2 million from a year earlier. Physicians prescribing Enerzair and Atectura reached 1,583 at the end of the first quarter, 39% growth for the quarter and a 799% increase year-over-year. Total annual Enerzair and Atectura prescriptions surpassed 34,000 at the end of 1Q 2023, up 1,917% year-over-year. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 17, 2023 11:40 AM Eastern Daylight Time

Video

UAT Group Subsidiary, Ossifix Orthopedics Begins Expansion

Umbra Applied Technologies Group, Inc.

McapMediaWire -- Umbra Applied Technologies Group, Inc. (OTC: UATG ) (UAT Group) announced today that its subsidiary, Ossifix Orthopedics has begun expanding beyond Texas starting with southern and north-eastern part of the United States. Over the past several weeks, the Company has onboarded five new account managers across eleven cities in Texas with expansion into the New England area currently underway. The Company has slated the second fiscal quarter of the year for expansion across four major metropolitan cities in Louisiana and across twenty-one major metropolitan cities in Florida. Ossifix CEO, Mark Estrada, stated: “We are currently in the process of expanding operations and onboarding distribution channels in select target regions. Additionally, in Q2 we will launch two unique foot and ankle product lines.” The Company projects more than one-hundred surgeries to be completed in Q2 alone with a 20% increase month over in growth. Results from initial surgeries have demonstrated early ambulation trend with many patients driving the next day. Results of the surgeries have dramatically increased interest in the Javelin pin which formed the basis for the Company’s decision to start expansion and led to the Company to begin increasing its salesforce. Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting. Manufactured of 100% allograft bone, Ossifix implants are designed for small bone, extremities, and sports medicine markets, but have applications in the craniofacial, spine and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally. Ossifixs’ unique manufacturing process and designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Paciﬁc, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% per year and is expected to reach $4.696 billion in sales this year. Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "The growth and interest that Ossifix has experienced is unprecedented. With the launch of their additional product suites coming later this year, Ossifix will be a disrupting force within a niche but significant market segment”. Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S. with international sales slated to begin later this year. For more information about Ossifix Technologies go here: https://ossifixtech.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

March 17, 2023 08:00 AM Eastern Daylight Time

American Center for Cures Co-Founder Appointed by President Biden to National Cancer Advisory Board

The American Center for Cures

The American Center for Cures (ACC) today announced its long-time partner and co-founder Dr. Richard Boxer has been selected by President Joseph Biden to the National Cancer Advisory Board. In this role, Dr. Boxer will use his years of medical expertise to help guide the Director of the National Cancer Institute in the development of the organization’s national cancer research. Along with venerated entrepreneur Lou Weisbach, Dr. Boxer co-founded the ACC as a bipartisan initiative that aims to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. “Richard Boxer and I have worked together on this important endeavor for more than a decade. It’s an honor to see him elevated to the National Cancer Advisory Board,” said Lou Weisbach, CEO and Co-Founder of ACC. “I’ve been working in a bipartisan way with leaders of both parties and the quote from Tom Price, former Secretary of Health, tells you all you need to know about our mission: ‘When this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.’” Dr. Boxer, a UCLA Clinical Professor and Co-Founder of the American Center for Cures added: “I’ve dedicated my professional career to compassionate and uncompromising care for cancer patients and educating the public and the medical community and preventing and curing disease is a critical single issue that all Americans can agree on. As a practicing urologist treating cancer patients and cancer survivor myself, the mission of the ACC and my role in its success is very personal.” Dr. Boxer, a Clinical Professor at the David Geffen School of Medicine at UCLA, himself a three-time cancer survivor, has been practicing medicine for 44 years, caring for more than 7,000 patients with cancer and tens of thousands of patients with other illnesses. He represented the U.S. at the World Health Organization as a private citizen, a finalist for Surgeon General of the United States in both a Democratic and Republican Administration, and he was recently on the Board of Directors of the American Society of Clinical Oncology Conquer Cancer Foundation. Dr. Boxer has published nearly 100 journal articles and book chapters on medical research and has also written extensively on health policy in national press outlets. He helped create the initial clinical protocols for telemedicine, becoming the Chief Medical Officer of numerous telemedicine companies. In April 2021, he was awarded the Distinguished Alumni Award by the University of Wisconsin’s Medical School, its highest honor. “This is a critical single issue that all Americans can agree on, whether they be black or white, rich or poor, Democrat or Republican,” declared Weisbach. “With kudos to all medical breakthroughs of the past, we still haven’t gotten the job done in a business-like fashion as a nation when it comes to prevention and cures. That ends today. We are not asking congress or both parties to move forward on this initiative, we are insisting that it be passed unanimously. This issue impacts all 335 million Americans in the same way, including everyone in The White House, as well as members of Congress and their families. If we cannot unite on this issue as Americans, then I submit there are no issues on which we can unite.” About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 15, 2023 02:33 PM Eastern Daylight Time

News Release

NuggMD Launches Leading Marijuana Telemedicine Service in Georgia

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, has launched its service in Georgia. For $139, Georgians can now use NuggMD’s platform to connect with a medical professional who can recommend cannabis for treatment of the state’s qualifying conditions. The launch comes amid a tense political, legal, and regulatory climate in Georgia for cannabis businesses and consumers. In 2019, Gov. Brian Kemp (R) signed into law HB 324, which legalized low-THC medical cannabis oil in the state. However, that law has yet to be successfully implemented, with only two production facilities having been awarded licenses in the subsequent four years. While newly proposed legislation, HB 196, seeks to allow more cannabis licenses, its political fate is uncertain. Additionally, Georgia remains one of the dwindling states that still impose jail time for simple possession of unlicensed cannabis. Despite lacking a single legal cannabis dispensary and the fact that no provision in Georgia law suggests how a patient might lawfully obtain cannabis, an estimated 25,000 medical cannabis patients currently reside in Georgia, and the overall demand for legal cannabis is far greater. Alex Milligan, co-founder and CMO of NuggMD, said, "Georgia still has unfair criminal statutes for the simple possession of cannabis, which runs counter to the 2019 law that legalized some forms of the substance. As one of the only services Georgians can rely on to lawfully access cannabis, the irony of this contradiction is not lost on us. One way or another—and in accordance with state law—the availability of legal cannabis will soon be a reality in Georgia. We’ve expanded our operations there so that Georgians can prepare for this eventuality by receiving cannabis recommendations from credible, licensed medical professionals.” NuggMD's platform is available from 8 am until 10 pm local time, seven days a week. No appointment is needed, and patients who are deemed not to qualify for Georgia's medical cannabis program won't be charged for their evaluation. Since its founding in 2015, NuggMD has helped more than 1,000,000 patients access medical marijuana in nearly half of the nation's states. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham andrew.g@getnugg.com Company Website http://www.nuggmd.com

March 15, 2023 02:30 PM Eastern Daylight Time

News Release

BioVie Day says webinar registration now open for investors

BioVie Inc

BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’s disease, epigenetics, longevity, and liver disease. Investors will also be able to participate in a live question and answer session will follow the leadership teams’ formal presentations. To register for BioVie Day check out this link: https://lifescievents.com/event/biovie-day/ Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

March 15, 2023 10:59 AM Eastern Daylight Time

Video

Spring Cleaning Your Brain Health

YourUpdateTV

Spring is almost here and it’s time to clear out the cobwebs and rethink and re-energize your health and wellness routines for the rest of the year. And while many people focus on physical health, it’s also important to think about your mental and emotional well-being. Recently, Nutrition Expert, Mia Syn, teamed with The Vitamin Shoppe on a nationwide satellite media tour to help boost your health and wellness going into Spring. A video accompanying this announcement is available at: https://youtu.be/2NqDH4Uah-A Staying Hydrated Brain health is a critical piece of your overall health that can not only improve your physical health but can also create positive cognitive and emotional impacts that contribute to overall well-being. One thing many people forget about is proper Hydration. Hydration is essential as it assists blood flow and oxygen to the brain, which helps both brain and memory function. Waterdrop is a great way to drink more water and reach your daily hydration goals. Made from natural plant and fruit extracts for flavor, Waterdrop cubes are just dropped into a glass of water and provide you with energy from caffeine, plus essential vitamins and hydration – all without sugar. They come individually wrapped so you can bring them anywhere and just drop into your refillable water bottle! Impact of Stress on the Brain Stress can have many effects on brain health and our overall health, including physical symptoms like headaches and pains, but also things like memory, mood, anxiety levels, and social behaviors. Solaray’s SHARPMIND line of supplements is formulated with clinically studied nutrients, adaptogens and nootropics, to support mental and emotional well-being. The SHARPMIND Mood formula is formulated with holy basil and reishi mushrooms to support stress and mood levels. SHARPMIND Focus has Lion’s Mane mushrooms and Bacopa to support memory and cognitive health. There are also other unique formulas for sleep, energy, and stress, to support different areas of your well-being. Optimizing Physical and Mental Performance Like other parts of your body, your brain needs proper nutrition to perform at its best whether at work, home, or on-the-go. So, whether you want to improve cognitive function, or simply feel healthier and more energetic, we need to make sure our brains are getting what they need. Focus Factor from Synergy CHC contains a clinically-tested and patented combination of neuro-nutrients plus vitamins and minerals. This formula not only helps boost your memory and focus, but it can also replace your everyday multivitamin, making it an excellent 2-for-1 supplement option to help optimize your performance throughout the day. Sleep and Aging Many of us struggle to get the quality sleep we need, and after a night of tossing and turning, we often lack the energy, confidence, and clear thinking we need to accomplish our goals. Somnapure Sleep Gummies from Force Factor can help. Their 100% drug-free, non-habit-forming formula contains a 10 mg dose of melatonin which helps you relax before bed, so you can fall asleep faster and stay asleep longer. And finally, as people age, our physical and mental performance may require more support. But there are ways for us to address these deficits and maintain our edge. Forebrain Advanced from Force Factor is formulated with brain-boosting herbs and advanced nootropics that can help you achieve better cognitive performance and improve memory and recall. For more information, visit vitaminshoppe.com About Mia Syn Mia Syn, MS, RDN is a nationally recognized nutrition expert and founder of Nutrition by Mia, a popular online wellness destination frequented by millions of readers around the globe. She holds a Master of Science in human nutrition from Columbia University and has been featured by dozens of major media outlets including Women's Health Magazine, Cosmopolitan and SHAPE. As one of the most recognized and trusted young nutritionists in the country, she has helped hundreds of her clients and millions of her readers lose weight, improve their health and develop better sustainable eating habits for life. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 15, 2023 09:37 AM Eastern Daylight Time

Video

1 ... 110 111 112 113 114 ... 236